


| | | |
|--|---|---|
| ISSUE DATE December 27, 2021 | EFFECTIVE DATE October 29, 2021 | NUMBER 01-21-51, 05-21-09, 08-21-53, 09-21-50, 11-21-39, 24-21-47, 26-21-05, 30-21-44 31-21-53, 33-21-50 |
| SUBJECT Pediatric SARS-CoV-2 Vaccine Manufactured by Pfizer, Inc. | | BY  Sally A. Kozak, Deputy Secretary Office of Medical Assistance Programs |

IMPORTANT REMINDER: All providers must revalidate the Medical Assistance (MA) enrollment of each service location every 5 years. Providers should log into PROMISe to check the revalidation dates of each service location and submit revalidation applications at least 60 days prior to the revalidation dates. Enrollment (revalidation) applications may be found at: <https://www.dhs.pa.gov/providers/Providers/Pages/PROMISe-Enrollment.aspx>.

PURPOSE:

The purpose of this bulletin is to inform Medical Assistance (MA) providers that the Department of Human Services (Department) added Current Procedural Terminology (CPT) codes 0071A and 0072A to the MA Program Fee Schedule for the administration of the pediatric novel coronavirus (SARS-CoV-2) vaccine manufactured by Pfizer, Inc.

SCOPE:

This bulletin applies to all physicians, certified registered nurse practitioners, certified nurse midwives, outpatient hospital-based clinics, independent medical surgical clinics, federally qualified health centers, rural health clinics, home health agencies, ambulance providers, renal dialysis centers, psychiatric outpatient clinics, drug and alcohol outpatient clinics, partial psychiatric hospitals, and licensed pharmacies enrolled in the MA Program who may administer SARS-CoV-2 vaccines to MA beneficiaries in the Fee-for-Service (FFS) or managed care delivery systems. Providers rendering services to MA beneficiaries in the managed care delivery system should contact the appropriate managed care organization with any billing questions.

BACKGROUND/DISCUSSION:

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

The appropriate toll-free number for your provider type.

Visit the Office of Medical Assistance Programs website at:

<https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/Contact-Information-for-Providers.aspx>

On October 6, 2021, the American Medical Association announced the addition of procedure codes 0071A and 0072A for the administration of the pediatric SARS-CoV-2 vaccine manufactured by Pfizer, Inc. The codes are distinct to the SARS-CoV-2 vaccines below. This level of specificity offers the ability to track each vaccine, even when the vaccine product is not reported, such as when the vaccine is available at no cost.

On October 29, 2021, the U.S. Food and Drug Administration amended the emergency use authorization for the Pfizer, Inc. SARS-CoV-2 vaccine to allow for the addition of the pediatric version of the vaccine.

In response, the Department added CPT codes 0071A and 0072A to the MA Program Fee Schedule, which may be used for dates of service on and after October 29, 2021. These codes are to be used by providers in both the FFS and managed care delivery systems to enable the Department to identify the specific SARS-CoV-2 vaccines that have been administered.

PROCEDURE:

Effective for dates of service on or after October 29, 2021, MA providers in both the FFS and managed care delivery systems are to bill for the administration of the pediatric SARS-CoV-2 vaccine manufactured by Pfizer, Inc. to MA beneficiaries using the CPT codes below.

| Vaccine Manufacturer | Code | Code Description |
|-----------------------------|-------------|---|
| Pfizer, Inc. | 0071A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose |
| | 0072A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose |

Attached is the “Addition to the Medical Assistance Program Fee Schedule: Procedure Codes for the Administration of the Pediatric SARS-CoV-2 Vaccine Manufactured by Pfizer, Inc., Effective October 29, 2021”. The attachment identifies the procedure code, national code description, provider type, provider specialty, place of service, pricing and/or informational modifiers if applicable, and MA fee for the procedure code for providers submitting MA FFS claims.

Federally Qualified Health Centers (FQHC) and Rural Health Clinics (RHC) are to bill with the applicable CPT codes when a SARS-CoV-2 vaccine is administered to a MA beneficiary independent from other services. When a SARS-CoV-2 vaccine is administered during a visit where eligible services that constitute an encounter are rendered, FQHCs and

RHCs are to bill procedure code T1015 to be paid their provider-specific prospective payment system rate, but those providers are to add the appropriate SARS-CoV-2 vaccine CPT code on a separate claim line for tracking purposes, with no additional payment made for the administration of the vaccine booster.

MA providers in both the FFS and managed care delivery systems who administer a pediatric dose of a SARS-CoV-2 vaccine to a MA beneficiary who is homebound should bill procedure code M0201 along with the applicable SARS-CoV-2 pediatric vaccine administration code. For additional information related to billing for the administration of SARS-CoV-2 vaccines to a MA beneficiary who is homebound, providers should refer to MA Bulletin 01-21-04, "SARS-CoV-2 Vaccine Administration for Beneficiaries who are Homebound" for billing instructions. The bulletin may be accessed at the link below:

<https://www.dhs.pa.gov/docs/Publications/Documents/FORMS%20AND%20PUBS%20OMAP/MAB2021072901.pdf>.

Providers may access the online version of the MA Program Fee Schedule on the Department's website at:

<https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/MA-Fee-Schedule.aspx>.

For information on how licensed pharmacies enrolled in the MA Program who provide services to MA beneficiaries should bill for the administration of SARS-CoV-2 vaccines by a pharmacist, please refer to MA Bulletin 01-20-60, "SARS-CoV-2 Vaccine Administration by Pharmacists", issued December 30, 2020, at the link below:

<https://www.dhs.pa.gov/docs/Publications/Documents/FORMS%20AND%20PUBS%20OMAP/MAB2020123001.pdf>.

MA providers may also bill the MA Program for the vaccine for MA eligible beneficiaries by indicating, on the claim submission, the appropriate National Drug Code and the units dispensed for the vaccine. Providers may access the online version of the MA Drug Fee Schedule on the Department's website at: <https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/default.aspx>.

Providers may not bill the Department for administration of a SARS-CoV-2 vaccine they receive at no cost or for the administration of a SARS-CoV-2 vaccine for which they will be paid by another entity to administer.

The Pennsylvania Department of Health (DOH) Vaccines for Children (VFC) Program includes Pfizer's pediatric SARS-CoV-2 vaccine on the list of vaccines available at no cost to VFC-enrolled providers for administration to children, including MA children, under 19 years of age. MA providers are encouraged to participate in the VFC program. Enrollment information is provided in the VFC Provider Handbook which can be found on the DOH website at: <https://www.health.pa.gov/topics/Documents/Programs/Immunizations/VFC%20Handbook%20-%20Section%202.pdf>. Additionally, in order for VFC providers to receive and administer SARS-CoV-2 vaccines, they must sign and adhere to the requirements of the *CDC COVID-19*

Vaccination Program Provider Agreement which can be found on the CDC website at:
<https://www.cdc.gov/vaccines/covid-19/provider-enrollment.html>.

Additional information and guidance pertaining to the SARS-CoV-2 vaccines can be found at the following links:

- American Medical Association
<https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-coding-and-guidance>.
- Centers for Disease Control and Prevention
<https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html>.
- Centers for Medicare & Medicaid Services
<https://www.medicare.gov/resources-for-states/disaster-response-toolkit/coronavirus-disease-2019-covid-19/index.html>.
- Pennsylvania Department of Health
<https://www.health.pa.gov/Pages/default.aspx>.

ATTACHMENT:

Addition to the Medical Assistance Program Fee Schedule: Procedure Codes for the Administration of the Pediatric SARS-CoV-2 Vaccines Manufactured by Pfizer, Inc., Effective October 29, 2021

**Addition to the Medical Assistance Program Fee Schedule: Procedure Codes for the Administration of the Pediatric SARS-CoV-2 Vaccine
Manufactured by Pfizer, Inc. , Effective October 29, 2021**

| Procedure Code | National Code Description | Provider Type | Provider Specialty | Place of Service | Pricing Modifier | Informational Modifier | MA Fee | Prior Authorization Required | Limits |
|----------------|--|---------------|--------------------|--------------------|------------------|------------------------|---------|------------------------------|--------------|
| 0071A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | 01 | 183 | 12, 22 | | | \$40.00 | No | once per day |
| 0071A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | 05 | 050, 051 | 12, 99 | | | \$40.00 | No | once per day |
| 0071A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | 08 | 080 | 12, 31, 32, 50, 99 | | | \$40.00 | No | once per day |
| 0071A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | 08 | 081 | 12, 31, 32, 72, 99 | | | \$40.00 | No | once per day |
| 0071A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | 08 | 082 | 12, 49 | | | \$40.00 | No | once per day |
| 0071A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | 08 | 110 | 11, 49, 99 | | | \$40.00 | No | once per day |
| 0071A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | 08 | 184 | 57, 99 | | | \$40.00 | No | once per day |

| | | | | | | | | | |
|-------|--|----|----------|--------------------|--|--|---------|----|--------------|
| 0071A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | 09 | All | 11, 12, 31, 32, 99 | | | \$40.00 | No | once per day |
| 0071A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | 11 | 110, 127 | 99 | | | \$40.00 | No | once per day |
| 0071A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | 11 | 113, 114 | 52 | | | \$40.00 | No | once per day |
| 0071A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | 24 | All | 11, 31, 32, 99 | | | \$40.00 | No | once per day |
| 0071A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | 24 | 240, 247 | 12 | | | \$40.00 | No | once per day |
| 0071A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | 26 | 260, 261 | 12, 99 | | | \$40.00 | No | once per day |
| 0071A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | 30 | 300 | 12, 65 | | | \$40.00 | No | once per day |
| 0071A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | 31 | All | 11, 12, 31, 32, 99 | | | \$40.00 | No | once per day |

| | | | | | | | | | |
|-------|---|----|----------|--------------------|--|--|---------|----|--------------|
| 0071A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose | 33 | 335 | 11, 12, 99 | | | \$40.00 | No | once per day |
| 0072A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | 01 | 183 | 12, 22 | | | \$40.00 | No | once per day |
| 0072A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | 05 | 050, 051 | 12, 99 | | | \$40.00 | No | once per day |
| 0072A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | 08 | 080 | 12, 31, 32, 50, 99 | | | \$40.00 | No | once per day |
| 0072A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | 08 | 081 | 12, 31, 32, 72, 99 | | | \$40.00 | No | once per day |
| 0072A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | 08 | 082 | 12, 49 | | | \$40.00 | No | once per day |
| 0072A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | 08 | 110 | 11, 49, 99 | | | \$40.00 | No | once per day |
| 0072A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | 08 | 184 | 57, 99 | | | \$40.00 | No | once per day |

| | | | | | | | | | |
|-------|---|----|----------|--------------------|--|--|---------|----|--------------|
| 0072A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | 09 | All | 11, 12, 31, 32, 99 | | | \$40.00 | No | once per day |
| 0072A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | 11 | 110, 127 | 99 | | | \$40.00 | No | once per day |
| 0072A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | 11 | 113, 114 | 52 | | | \$40.00 | No | once per day |
| 0072A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | 24 | All | 11, 31, 32, 99 | | | \$40.00 | No | once per day |
| 0072A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | 24 | 240, 247 | 12 | | | \$40.00 | No | once per day |
| 0072A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | 26 | 260, 261 | 12, 99 | | | \$40.00 | No | once per day |
| 0072A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | 30 | 300 | 12, 65 | | | \$40.00 | No | once per day |
| 0072A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | 31 | All | 11, 12, 31, 32, 99 | | | \$40.00 | No | once per day |

| | | | | | | | | | |
|-------|---|----|-----|------------|--|--|---------|----|--------------|
| 0072A | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | 33 | 335 | 11, 12, 99 | | | \$40.00 | No | once per day |
|-------|---|----|-----|------------|--|--|---------|----|--------------|